38 73,629
Loss from operations (19,701) (21,644) (74,523) (73,442)
Interest income 2,022 1,353 4,744 4,641
Interest expense (1,551) (452) (2,534) (1,354)
Net loss $(19,230) $(20,743) $(72,313) $(70,155)
Basic and diluted net
loss per share $(0.23) $(0.29) $(0.88) $(0.98)
Shares used in
computation of basic
and diluted net
loss per share 82,965 71,320 82,356 71,236
September 30, December 31,
2007 2006
Balance Sheet Data:
Cash and cash
equivalents $90,950 $60,964
Short-term investments 30,184 45,492
Long-term investments 17,694 14,827
Total assets 181,059 163,643
Convertible notes 85,250 -
Total stockholders' equity 64,611 125,717
'/>"/>SOURCE Dendreon Corporation Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2.
Dendreon Announces Webcast Presentation at UBS Life Sciences Conference3.
Dendreon Secures $130 Million Committed Equity Financing Facility4.
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences5.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound6.
QMed, Inc. Reports July Medicare SNP Enrollments7.
Phlo Affiliate Reports Expanded Coverage to Oregon Border8.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results9.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 200710.
Carrington Reports Second Quarter 2007 Results11.
Avitar Reports Third Quarter Financial Results for Fiscal 2007